Angiotensin II receptor antagonists in hypertension

Détails

ID Serval
serval:BIB_A291601EB18F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Angiotensin II receptor antagonists in hypertension
Périodique
Kidney International. Supplement
Auteur(s)
Burnier  M., Brunner  H. R.
ISSN
0098-6577 (Print)
Statut éditorial
Publié
Date de publication
12/1998
Volume
68
Pages
S107-11
Notes
Journal Article
Review --- Old month value: Dec
Résumé
Blockade of the renin-angiotensin system is now recognized as an effective approach to the treatment of hypertension and congestive heart failure. Today, it is possible to antagonize the effects of angiotensin II more specifically by blocking its receptors by using nonpeptide receptor antagonists. These compounds that first have been used to recognize the various subtypes of angiotensin II receptors are now available clinically. Four of them have recently been launched on the market and several others are preregistered for the treatment of hypertension. These new molecules are as effective as ACE inhibitors, calcium antagonists and beta-blockers in lowering blood pressure in hypertensive patients. When compared to ACE inhibitors, they appear to have comparable favorable effects on systemic and renal hemodynamic properties. One of the major characteristics of angiotensin II receptor antagonists as a class is the excellent tolerability with an incidence of side effects that is generally similar to that of placebo. Large clinical trials are now underway to demonstrate the long-term benefits of these agents in hypertension, heart failure and type II diabetic nephropathy.
Mots-clé
Antihypertensive Agents/*therapeutic use Humans Hypertension, Renal/*drug therapy Kidney/chemistry Receptors, Angiotensin/*antagonists & inhibitors
Pubmed
Création de la notice
25/01/2008 13:55
Dernière modification de la notice
03/03/2018 20:10
Données d'usage